Overcoming intractable diseases
with “Regeneration-Inducing Medicine

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine”.

Overcoming intractable diseases
with “Regeneration-Inducing Medicine

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine”.

IR News

May 08, 2024 Timely Disclosure Information StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease) 
March 21, 2024 IR News StemRIM Announces Symposium on “Regeneration-Inducing Medicine” at the 23rd Congress of the Japanese Society for Regenerative Medicine 
March 15, 2024 Financial Results Presentation Materials Presentation Materials for Six Months Ended January 31, 2024 
March 13, 2024 Financial Results Non-consolidated Financial Results for the Six Months Ended January 31, 2024[Japanese GAAP] 
March 13, 2024 Timely Disclosure Information StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy 
IR News Here

NEWS Release

April 25, 2023 NEWS Release
News Release Here

Video

Video Here

We aim to bring a happy future to patients suffering from intractable diseases.

StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine”.
“Regeneration-Inducing Medicine” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.

What is “Regeneration-Inducing
Medicine”?
Issues of Conventional
Cell Therapy
The Superiority of
“Regeneration-Inducing Medicine

Business

Corporate Information Investor Relations